IP Library Granted Patent US 7,855,058
Granted Patent B2
US 7,855,058 · App. 11/759,726 · Granted Dec 21, 2010

Human cyclin-dependent kinase (hPNQALRE)

Assignee: Novartis Vaccines and Diagnostics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,855,058
App. No.
11/759,726
Granted
Dec 21, 2010
Kind
B2
Abstract

A human gene encoding a novel cyclin-dependent kinase termed hPNQALRE and its expression products can be used to provide reagents and methods for detecting neoplasia. Compositions and methods for treating proliferative disorders and neoplasia are also provided.

Claims (20)

1. An isolated nucleic acid molecule comprising a nucleotide sequence at least 98% identical to SEQ ID NO: 1 or the full complement of SEQ ID NO: 1.

2. The isolated nucleic acid molecule of claim 1 wherein the nucleotide sequence is 100% identical to SEQ ID NO: 1 or the full complement of SEQ ID NO: 1.

3. The isolated nucleic acid molecule of claim 1 which encodes a polypeptide having cyclin-dependent kinase activity.

4. The isolated nucleic acid molecule of claim 1 wherein the nucleotide sequence at least 98% identical to SEQ ID NO: 1 shows the same expression profile as the nucleotide sequence of SEQ ID NO: 1 or the full complement of SEQ ID NO: 1.

5. The isolated nucleic acid molecule of claim 1 wherein said nucleic acid molecule is DNA.

6. The isolated nucleic acid molecule of claim 1 wherein said nucleic acid molecule is RNA.

7. An expression vector comprising a nucleic acid molecule of claim 1 .

8. The expression vector of claim 7 wherein said vector is a plasmid.

9. The expression vector of claim 7 wherein said vector is a viral particle.

10. A host cell transformed with an expression vector of claim 7 .

11. A method of making a recombinant vector comprising inserting a nucleic acid molecule of claim 1 into a vector in operable linkage to a promoter.

12. A recombinant vector produced by the method of claim 11 .

13. A method of making a recombinant host cell comprising introducing the recombinant vector of claim 12 into a host cell.

14. A recombinant host cell produced by the method of claim 11 .

15. A recombinant method of producing a polypeptide, comprising culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed and recovering said polypeptide.

16. A method of producing a polypeptide that comprises SEQ ID NO: 2, and immunogenic fragments thereof, said method comprising the steps of:

(b) introducing a recombinant expression vector of claim 9 into a compatible host cell;

(c) growing said host cell under conditions for expression of said polypeptide; and

(d) recovering said polypeptide.

17. An isolated nucleic acid molecule which encodes SEQ ID NO: 2.

Assignments (1)
CHANGE OF NAME Recorded Nov 11, 2010
From: CHIRON CORPORATION
To: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Reel/Frame 025353/0521 →
Continuity (4)
Division 1066389600 · Sep 16, 2003
Continuation 0946406500 · Dec 15, 1999
Provisional Application 6011249700 · Dec 16, 1998
Related Publication 20080176279A1 · Jul 24, 2008